Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Innovative Bioluminescence Resonance Energy Transfer Assay Reveals Differential Agonist-Induced D2 Receptor Intracellular Trafficking and Arrestin-3 Recruitment.

De Vries L, Finana F, Cathala C, Ronsin B, Cussac D.

Mol Pharmacol. 2019 Sep;96(3):308-319. doi: 10.1124/mol.119.115998. Epub 2019 Jul 2.

PMID:
31266815
2.

Dosage-dependent regulation of cell proliferation and adhesion through dual β2-adrenergic receptor/cAMP signals.

Bruzzone A, Saulière A, Finana F, Sénard JM, Lüthy I, Galés C.

FASEB J. 2014 Mar;28(3):1342-54. doi: 10.1096/fj.13-239285. Epub 2013 Dec 5.

PMID:
24308976
3.

Deciphering biased-agonism complexity reveals a new active AT1 receptor entity.

Saulière A, Bellot M, Paris H, Denis C, Finana F, Hansen JT, Altié MF, Seguelas MH, Pathak A, Hansen JL, Sénard JM, Galés C.

Nat Chem Biol. 2012 Jul;8(7):622-30. doi: 10.1038/nchembio.961. Epub 2012 May 27.

PMID:
22634635
4.

μ-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways.

Cussac D, Rauly-Lestienne I, Heusler P, Finana F, Cathala C, Bernois S, De Vries L.

Cell Signal. 2012 Aug;24(8):1648-57. doi: 10.1016/j.cellsig.2012.04.010. Epub 2012 Apr 25.

PMID:
22560877
5.

Cellular BRET assay suggests a conformational rearrangement of preformed TrkB/Shc complexes following BDNF-dependent activation.

De Vries L, Finana F, Cachoux F, Vacher B, Sokoloff P, Cussac D.

Cell Signal. 2010 Jan;22(1):158-65. doi: 10.1016/j.cellsig.2009.09.027. Epub 2009 Sep 22.

PMID:
19781635
6.

Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.

Cussac D, Palmier C, Finana F, De Vries L, Tardif S, Léger C, Bernois S, Heusler P.

J Pharmacol Exp Ther. 2009 Oct;331(1):222-33. doi: 10.1124/jpet.109.156307. Epub 2009 Jul 15.

PMID:
19605522
7.

Pharmacological characterization of protease activated receptor-1 by a serum responsive element-dependent reporter gene assay: major role of calmodulin.

De Vries L, Palmier C, Finana F, Le Grand B, Perez M, Cussac D.

Biochem Pharmacol. 2006 May 14;71(10):1449-58. Epub 2006 Mar 9.

PMID:
16524561
8.

Endogenous RGS proteins facilitate dopamine D(2S) receptor coupling to G(alphao) proteins and Ca2+ responses in CHO-K1 cells.

Boutet-Robinet EA, Finana F, Wurch T, Pauwels PJ, De Vries L.

FEBS Lett. 2003 Jan 2;533(1-3):67-71.

9.

Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.

Pauwels PJ, Wurch T, Tardif S, Finana F, Colpaert FC.

Naunyn Schmiedebergs Arch Pharmacol. 2001 May;363(5):526-36.

PMID:
11383713
10.

Dynamic dopamine-antagonist interactions at recombinant human dopamine D(2short) receptor: dopamine-bound versus antagonist-bound receptor states.

Pauwels PJ, Finana F, Tardif S, Wurch T, Colpaert FC.

J Pharmacol Exp Ther. 2001 Apr;297(1):133-40.

PMID:
11259537
11.

Agonist efficacy at the alpha2A-adrenoceptor:G alpha15 fusion protein: an analysis based on Ca2+ responses.

Pauwels PJ, Finana F, Tardif S, Colpaert FC, Wurch T.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Jun;361(6):672-9.

PMID:
10882043
12.

Ligand-receptor interactions as controlled by wild-type and mutant Thr(370)Lys alpha2B-adrenoceptor-Galpha15 fusion proteins.

Pauwels PJ, Tardif S, Finana F, Wurch T, Colpaert FC.

J Neurochem. 2000 Jan;74(1):375-84.

Supplemental Content

Loading ...
Support Center